Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 10/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7606919 | 0.81 | GLO1 (0.55) | GLO1ALDH1A1 | |
| SCHEMBL11299251 | 0.80 | CYP3A4 (0.56) | GLO1LMNAALDH1A1TSHRMAPK1 | |
| SCHEMBL25759566 | 0.77 | TSHR (0.33) | LMNATRPV4ALDH1A1TP53TSHR | |
| SCHEMBL25759568 | 0.77 | SLC9A1 (0.39) | TRPV4ALDH1A1 | |
| SCHEMBL742725 | 0.75 | KMT2A (0.49) | LMNAALDH1A1L3MBTL1TSHRKMT2A | |
| SCHEMBL29642997 | 0.75 | KMT2A (0.49) | LMNAALDH1A1L3MBTL1TSHRKMT2A | |
| SCHEMBL251516 | 0.74 | LMNA (0.50) | LMNATRPV4ALDH1A1TSHRHSD17B10 | |
| SCHEMBL3932613 | 0.74 | TRPV4 (0.53) | LMNATRPV4ALDH1A1TP53CYP3A4 | |
| SCHEMBL31674581 | 0.72 | KMT2A (0.51) | LMNAALDH1A1TSHRMAPK1KMT2A | |
| SCHEMBL8493031 | 0.72 | L3MBTL1 (0.52) | LMNATRPV4ALDH1A1L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | GLO1 2354/4885LMNA 3435/4885TRPV4 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.